- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. ] FSL-1 TFA
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P2036A |
| Brand: | MCE |
| CAS: | - |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 1780.18 |
| Molecular Formula | C82H141F3N14O20S |
| SMILES | - |
2 Publications Citing Use of MCE
Summary
IC50 & Target
|
TLR2
|
TLR6
|
MMP-9
|
In Vitro
FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)
[1]
.
FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile
[1]
.
FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells
[2]
.
FSL-1 activates the MAP kinase/NF-κB signaling pathway
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | V11I, V12I or V19I immortalized human vaginal EC |
| Concentration: | 6 μg or 0.1 μg |
| Incubation Time: | Added at 24, 6 or just prior to HSV-2 inoculation (10 4 pfu/well) |
| Result: | The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge. |
In Vivo
FSL-1 application significantly protectes against genital HSV-2 challenge in mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female Swiss-Webster mice (weighing 20-25 g) [1] |
| Dosage: | 2 or 6 μg |
| Administration: | Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment. |
| Result: |
The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control.
The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application. |
Appearance
Solid
Shipping
Shipping with dry ice.
Storage
-80°C
Solvent & Solubility
H 2 O : 50 mg/mL ( 28.09 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.5617 mL | 2.8087 mL | 5.6174 mL |
| 5 mM | 0.1123 mL | 0.5617 mL | 1.1235 mL |
| 10 mM | 0.0562 mL | 0.2809 mL | 0.5617 mL |
References
- [1] William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195.
- [2] Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.